COYA icon

Coya Therapeutics

5.24 USD
+0.08
1.55%
At close Dec 20, 4:00 PM EST
After hours
5.24
+0.00
0.00%
1 day
1.55%
5 days
-8.23%
1 month
-13.10%
3 months
-14.24%
6 months
-17.87%
Year to date
-24.71%
1 year
-23.73%
5 years
14.66%
10 years
14.66%
 

About: Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Employees: 6

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more capital invested

Capital invested by funds: $19.8M [Q2] → $21.4M (+$1.57M) [Q3]

0.3% more ownership

Funds ownership: 21.48% [Q2] → 21.78% (+0.3%) [Q3]

0% more funds holding

Funds holding: 19 [Q2] → 19 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$14
167%
upside
Avg. target
$15.67
199%
upside
High target
$18
244%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
D. Boral Capital
Jason Kolbert
25% 1-year accuracy
38 / 150 met price target
186%upside
$15
Buy
Maintained
18 Dec 2024
HC Wainwright & Co.
Raghuram Selvaraju
39% 1-year accuracy
121 / 308 met price target
244%upside
$18
Buy
Reiterated
11 Nov 2024
Chardan Capital
Keay Nakae
29% 1-year accuracy
21 / 72 met price target
167%upside
$14
Buy
Maintained
7 Nov 2024

Financial journalist opinion

Neutral
Business Wire
4 days ago
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Toplin.
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Neutral
Business Wire
3 weeks ago
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55.
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
Neutral
Business Wire
1 month ago
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan. Dear Fellow Stockholder, Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose b.
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Neutral
Business Wire
1 month ago
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's.
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
Neutral
Business Wire
1 month ago
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1, 2024. Dr. Swaminathan was instrumental in executing several significant commercial transactions in his career, including Coya's licensing transaction w.
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
Positive
Seeking Alpha
1 month ago
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
Coya Therapeutics, Inc.'s stock has sold off on misinterpreted data from a small trial with COYA 301. The presented clinical data validates safety, tolerability, and the inverse dose response of IL-2 and Treg function. The much more efficacious COYA 302 is Coya's actual therapy candidate.
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
Negative
Benzinga
1 month ago
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Positive
Reuters
1 month ago
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial
Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enrolled in a small, mid-stage trial.
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial
Neutral
Business Wire
1 month ago
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease were announced today at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar an.
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)
Neutral
Business Wire
1 month ago
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results wil.
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease
Charts implemented using Lightweight Charts™